Positive FDA Pre-IND Feedback Announced for SVC112 Program in Advanced Solid Tumors
“We are very encouraged by the FDA’s feedback and believe this represents an important milestone in the development of SVC112,” said Antonio Jimeno, MD, PhD, CU Anschutz Professor, Medicine-Medical Oncology, and Board member of SuviCa. “The Agency’s responses support our development strategy and provide a clear regulatory path toward IND submission and initiation of our first-in-human clinical study, added Dr. Jimeno. “The innovative support network at the University of Colorado’s Boulder and Anschutz campuses has made all this possible,” said Tin Tin Su, PhD, CU Boulder Professor, lead inventor of SVC112, and co-founder of SuviCa.
Share:
More News
“FDA clearance of the IND for ORM-1153 is an important milestone for Orum, bringing another first-in-class DAC into the clinic and extending our approach into CD123-expressing hematologic malignancies,” said Olaf Christensen, M.D., Chief Medical Officer of Orum Therapeutics. “By combining cell-selective delivery with targeted protein degradation in a single molecule,
“We are excited to expand our clinical collaboration with Roche to evaluate a second KRAS combination with potential best-in-class MTA-cooperative PRMT5 inhibitor IDE892 for pancreatic cancer patients, where there remains a high unmet medical need. IDEAYA is advancing multiple rational combination strategies for the IDE892 program, including with MAT2A inhibitor
“These encouraging initial safety observations represent an important first step in the clinical evaluation of ZI-MA4-1 and our TCR-NK platform” said Namir Hassan, Chief Executive Officer of Zelluna. “The first patient received all three planned doses, and the independent committee’s recommendation enables us to continue recruitment at the first dose
“Receiving FTD is an important milestone for ERAS-0015 and reflects the urgent need for new therapies for patients with metastatic pancreatic cancer,” said Jonathan E. Lim, M.D., Erasca’s chairman, CEO, and co-founder. “Together with the encouraging clinical activity and favorable tolerability observed to date, this FTD helps to position us